Company profile

Ticker
TLGT
Exchange
CEO
Timothy Sawyer
Employees
Incorporated
Location
Fiscal year end
Former names
IGI INC, IGI LABORATORIES, INC
SEC CIK
IRS number
10355758

TLGT stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

13 Nov 20
6 Dec 20
31 Dec 20

News

Quarter (USD) Jun 20 Mar 20 Sep 19 Jun 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Teligent earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
26 Aug 20 Life Sciences Opportunities Fund Instittutional Ii Common Stock Sell Dispose S No 1.2478 85,106 106.2K 17,515
26 Aug 20 Life Sciences Opportunities Fund Instittutional Ii Common Stock Sell Dispose S No 1.2435 475,512 591.3K 98,390
25 Aug 20 Life Sciences Opportunities Fund Instittutional Ii Common Stock Sell Dispose S No 1.1266 15,184 17.11K 102,621
25 Aug 20 Life Sciences Opportunities Fund Instittutional Ii Common Stock Sell Dispose S No 1.1336 84,816 96.15K 573,902
21 Aug 20 Life Sciences Opportunities Fund Instittutional Ii Common Stock Sell Dispose S No 1.6569 18,432 30.54K 117,805
21 Aug 20 Life Sciences Opportunities Fund Instittutional Ii Common Stock Sell Dispose S No 1.6615 102,962 171.07K 658,718
19 Aug 20 Life Sciences Opportunities Fund Instittutional Ii Common Stock Sell Dispose S No 2.2459 13,251 29.76K 136,237
19 Aug 20 Life Sciences Opportunities Fund Instittutional Ii Common Stock Sell Dispose S No 2.2565 74,020 167.03K 761,680
16 Jul 20 Philip K Yachmetz RSU Common Stock Grant Aquire A No 0 23,505 0 23,505
16 Jul 20 Philip K Yachmetz Stock Option Common Stock Grant Aquire A No 2.34 36,325 85K 36,325
27.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 20 21 -4.8%
Opened positions 3 4 -25.0%
Closed positions 4 23 -82.6%
Increased positions 2 0 NEW
Reduced positions 9 16 -43.8%
13F shares
Current Prev Q Change
Total value 861K 4.05M -78.8%
Total shares 1.46M 1.67M -13.0%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Highbridge Capital Management 447.94K $134K NEW
MS Morgan Stanley 437.02K $315K -16.6%
Eversept Partners 305.42K $220K -14.0%
BLK Blackrock 82.75K $60K +0.0%
Vanguard 65.25K $47K -68.6%
Geode Capital Management 33.52K $24K 0.0%
Renaissance Technologies 30.34K $22K NEW
NJ State Employees Deferred Compensation Plan 24K $17K 0.0%
Boothbay Fund Management 13.37K $10K -7.1%
Tower Research Capital 10.38K $7K +298.0%
Largest transactions
Shares Bought/sold Change
Highbridge Capital Management 447.94K +447.94K NEW
Sanders Morris Harris 0 -405.24K EXIT
Vanguard 65.25K -142.84K -68.6%
MS Morgan Stanley 437.02K -86.87K -16.6%
Eversept Partners 305.42K -49.58K -14.0%
Renaissance Technologies 30.34K +30.34K NEW
UBS UBS 100 -11.78K -99.2%
Tower Research Capital 10.38K +7.77K +298.0%
BAC Bank Of America 1.2K -5.89K -83.1%
Boothbay Fund Management 13.37K -1.03K -7.1%

Financial report summary

?
Risks
  • Our business may be adversely affected by the recent coronavirus outbreak.
  • We rely on a limited number of customers for a large portion of our revenues.
  • Due to our dependence on a limited number of products, our business will be materially adversely affected if these products do not perform as well as expected.
  • The pharmaceutical industry in which we operate is intensely competitive. We are particularly subject to the pressures of direct competition. For example, the competition we encounter may have a negative impact upon the prices we may charge for our products, the market share of our products and our revenue and profitability.
  • As our competitors introduce their own generic equivalents of our generic pharmaceutical products, our revenues and gross margin from such products may decline, potentially rapidly.
  • Our strategy depends on our ability to successfully develop and launch new pharmaceutical products ahead of our competitors.
  • If pharmaceutical companies are successful in limiting the use of generics through their legislative, regulatory and other efforts, sales of our generic products may be adversely impacted.
  • Our generics business also faces increasing competition from brand-name manufacturers that do not face any significant regulatory approval or other barriers to enter into the generics market.
  • Our business and operations have experienced rapid growth, and if we do not appropriately manage any future growth, our business will be adversely affected.
  • Sales of our products may continue to be adversely affected by the continuing consolidation of our distribution network and the concentration of our customer base. The result of such developments could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.
  • We face intense competition in the consumer products business.
  • Lack of availability, issues with quality or significant increases in the cost of raw materials used in manufacturing our products could adversely impact our profit margins and operating results.
  • We depend on a limited number of suppliers for API. Generally, only a single source of API is qualified for use in each product due to the costs and time required to validate a second source of supply. Changes in API suppliers must usually be approved by the FDA through a Prior Approval Supplement to each ANDA.
  • Incidents related to hazardous materials could materially adversely affect our reputation, business, financial condition, operating results and cash flows.
  • We are subject to stringent regulatory requirements related to environmental protection and hazardous waste disposal. Failure to adhere to such requirements could harm our business and results of operations.
  • We are subject to extensive government regulation by the FDA and other federal, state and local regulatory authorities that increases our costs and could prevent us from marketing or selling our products.
  • We are subject to extensive government regulation by Health Canada and other federal, state provincial/territorial and local regulatory authorities that increases our costs and could prevent us from marketing or selling our products.
  • Inadequate resources for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • Our global operations expose us to certain risks, including challenges associated with political and economic instability, major hostilities and acts of terrorism.
  • Violations of cGMP and other government regulations could have a material adverse effect on our reputation, business, financial condition and results of operations.
  • During our efforts to expand our existing manufacturing facility, as well as potentially select and build out an additional manufacturing facility, we could experience business interruptions, as well as incur significant capital expenditures to complete the expansions, which may have a material adverse effect on our business, financial position and results of operations.
  • We could experience business interruptions at our manufacturing facility, which may have a material adverse effect on our business, financial position and results of operations.
  • We are currently in the process of expanding our manufacturing facilities. Any delays in the expansion process or in the receipt of certain regulatory approvals in connection therewith could have a material adverse effect on our business and results of operations.
  • Our reporting and payment obligations related to our participation in federal health care programs, including Medicare and Medicaid, are complex and often involve subjective decisions that could change. Any failure to comply with those obligations could subject us to investigation, penalties, and sanctions.
  • Our policies regarding returns, allowances and chargebacks, failure to supply penalties and marketing programs adopted by wholesalers may reduce revenues in future fiscal periods.
  • We are subject to federal and state healthcare fraud and abuse and false claims laws and may be subject to related litigation brought by the government or private individuals.
  • Our business activities may be subject to the Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws of other countries in which we operate.
  • Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.
  • Even after our products receive regulatory approval, such products may not achieve expected levels of market acceptance.
  • Product recalls could harm our business.
  • We are susceptible to product liability claims that may not be covered by insurance and could require us to pay substantial sums.
  • The manufacture and storage of pharmaceutical and other products are subject to inherent risk.
  • The testing required for the regulatory approval of our products is conducted by independent third parties. Any failure by any of these third parties to perform this testing properly and in a timely manner may have an adverse effect upon our ability to obtain regulatory approvals.
  • The failure to obtain, maintain or protect patents, trade secrets, know-how and other intellectual property could impact our ability to compete effectively.
  • Our product offerings and our customers’ products may infringe on the intellectual property rights of third parties.
  • Significant balances of intangible assets, including goodwill, are subject to impairment testing and may result in impairment charges, which may materially and adversely affect our results of operations and financial condition.
  • We may not be able to fully realize the expected benefits from the acquisition of certain products and/or companies.
  • Our approved products may not achieve commercialization at levels of market acceptance that allow us to achieve profitability, which could have a material adverse effect on our business, financial position and results of operations.
  • Future acquisitions and investments could disrupt our business and harm our financial condition and operating results.
  • We may become involved in legal proceedings from time to time which may result in losses, damage to our business and reputation and place a strain on our internal resources.
  • Our business and operations would suffer in the event of system failures.
  • Compliance with ongoing post-marketing obligations for our approved ANDAs, NDAs, NDSs, and ANDSs may uncover new safety information that could give rise to a product recall, updated warnings, or other regulatory actions that could have an adverse impact on our business.
  • Economic conditions could severely impact us.
  • Adverse conditions in the economy and disruption of financial markets could negatively impact our customers and therefore our results of operations.
  • If we are unable to hire additional qualified personnel, our ability to grow or maintain our business may be harmed.
  • We have identified material weaknesses in our internal control over financial reporting, and if we are unable to satisfy regulatory requirements relating to internal controls, our stock price could suffer.
  • We have identified material weaknesses in our internal control over financial reporting, which could continue to impact negatively our ability to report our results of operations and financial condition accurately and in a timely manner.
  • Currency fluctuations and changes in exchange rates could adversely affect our business, financial condition, results of operations, cash flows, and/or common stock price.
  • The Company is exposed to market risk from fluctuations in currency exchange rates.
  • Our ability to use our net operating loss carry forwards and certain other tax attributes may be limited.
  • Shares of our common stock can be relatively illiquid which may affect the trading price of our common stock.
  • We have not paid dividends to our common stockholders in the past nor do we expect to pay dividends in the foreseeable future, and any return on investment may be limited to potential future appreciation on the value of our common stock.
  • If we fail to comply with the reporting obligations of the Exchange Act and Section 404 of the Sarbanes-Oxley Act of 2002, or if we fail to achieve and maintain adequate disclosure controls and procedures and internal control over financial reporting, our business results of operations and financial condition, and investors’ confidence in us, could be materially adversely affected.
  • Our principal stockholders, directors and executive officers own a significant percentage of our stock and will be able to exercise significant influence over our affairs.
  • Due to the concentration of common stock owned by significant stockholders, the sale of such stock might adversely affect the price of our common stock.
  • Our stock price is, and we expect it to remain, volatile and subject to wide fluctuations, which may make it difficult for stockholders to sell shares of common stock at or above the price for which they were acquired.
  • We may not have the ability to raise the funds necessary to settle conversions of the Notes, purchase the Notes as required pursuant to the terms of the indentures governing the Notes or pay the redemption price for any Notes we redeem, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Notes.
  • Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our debt.
  • To the extent we issue shares of our common stock to satisfy all or a portion of our conversion obligation, conversions of the Notes will dilute the ownership interest of our existing stockholders, including holders who had previously converted their Notes.
  • Restrictive covenants in our Senior Credit Facilities may interfere with our ability to obtain additional advances under existing credit facilities or to obtain new financing or to engage in other business activities.
  • Our ability to satisfy our obligations pursuant to our Senior Credit Facilities depends on our future operating performance and on economic, financial, competitive, and other factors beyond our control.
  • We will continue to have the ability to incur debt; if we incur substantial additional debt, these higher levels of debt may affect our ability to pay the principal of and interest on the Notes and the Senior Credit Facilities.
Management Discussion
  • We had a net loss of $25.1 million, or $0.47 per share, during the year ended December 31, 2019 ("Current Year") compared to net loss of $36.3 million, or $0.68 per share, during the year ended December 31, 2018 ("Prior Year"). Product Sales, net, include Company Product Sales and Contract Manufacturing Sales, as follows:
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: advertised, Advertising, amid, Amneal, Apotex, Appco, artificially, assured, attached, Attorney, Aurobindo, billion, Boehringer, calendar, carcinogen, category, cautiously, concession, Consent, conspired, Costco, country, coverage, deferral, delisted, dermatology, deteriorated, Dr, duty, econzaole, effectuated, fact, Fe, fiduciary, fifty, Food, force, Fractional, Fred, George, GlaxoSmithKline, Glenmark, Gonzalez, higher, Indenture, Ingelheim, knew, knowingly, Korger, lab, Lannett, Mexico, Meyer, mirrored, modification, mutual, NDMA, nearest, negligence, negligent, nominal, notify, Novitium, nuisance, optimistic, Pfizer, pharmacy, prejudice, prescription, preserve, produced, promoted, protracted, proven, purportedly, ranitidine, rapidly, rebounding, reclassed, recruitment, Reddy, remove, rental, replace, Rite, rounded, routine, sanctioned, Sandoz, Sanofi, Santa, sector, seventeen, shown, Smith, statewide, stockholder, Store, stronger, subsidiary, telehealth, till, Unfair, unissued, unprecedented, unsafe, unspecified, USA, vi, welfare, Zantac
Removed: bad, incorporated, movement